Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Dulaglutide-associated body odor with dechallenge and rechallenge in a patient with type 2 diabetes.

Marusic S, Staresinic M, Berkovic MC

International journal of clinical pharmacology and therapeutics1 Aug 2026

PMID42087771 (opens in a new tab)DOI10.5414/cp204985 (opens in a new tab)PepBankPUB-42087771
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a man with type 2 diabetes who had dulaglutide-associated body odor, the odor did not recur after treatment was switched to semaglutide.

    In plain wordsIn one man with type 2 diabetes who got body odor on dulaglutide, the odor did not return after he switched to semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeRecurrence of body odor after switch to semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    treatment was switched to semaglutide, after which the body odor did not recur and glycemic control improved.
    1 context sentence
    Summary · context
    A 57-year-old man with a 6-year history of type 2 diabetes mellitus and hypertension was initiated on dulaglutide due to inadequate glycemic control and obesity.
  2. 02HumanCase report or seriesEfficacy outcome

    In a man with type 2 diabetes who switched from dulaglutide to semaglutide, glycemic control improved; the abstract gives no measure.

    In plain wordsIn one man with type 2 diabetes who switched from dulaglutide to semaglutide, blood sugar control improved.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGlycemic control after switch to semaglutide
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    treatment was switched to semaglutide, after which the body odor did not recur and glycemic control improved.
    1 context sentence
    Summary · context
    A 57-year-old man with a 6-year history of type 2 diabetes mellitus and hypertension was initiated on dulaglutide due to inadequate glycemic control and obesity.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.